Shanghai FosunPharma is vying with Shanghai Pharma Holding in a battle to acquire a minority stake in Atlanta’s Arbor Pharma, according to Bloomberg News. Apparently, US private equity company KKR has put its Arbor stake up for sale, with bids expected in the $600-$700 million range. Arbor makes both generic and patented drugs; it also has an active R&D program with seven candidates in clinical trials and another in pre-clinical development. KKR made an investment of undisclosed size in Arbor in late 2014.
Source: ChinaBio Today
